PepGen reports 46.5% splicing correction in Phase 2 DM1 trial and $104.8 M cash runway
PepGen Inc. announced topline results from the 10 mg/kg cohort of its Phase 2 FREEDOM2‑DM1 study, showing a mean splicing correction of 46.5% at Week 13. Five of six treated participants exceeded 20% correction and four exceeded 50%, with hand‑grip strength improving about 16.2% and the 10‑Meter Walk/Run Test up 6.8%. The company also disclosed a cash balance of $104.8 million, sufficient to fund operations into 2028, and reported a Q3 net loss of $19.4 million.
Why it matters
Stifel reiterated a Buy rating, noting the robust efficacy and safety data as a catalyst that drove the stock up more than 100% in pre‑market trading. The cash position assures continued development through 2028, reducing financing risk for investors.
Key facts
- 1Mean splicing correction in the 10 mg/kg cohort was 46.5% at Week 13. investing.com
- 2Five of six participants showed >20% correction and four showed >50% correction. investing.com
- 3Hand‑grip strength improved by approximately 16.2% at Week 16. investing.com
- 410‑Meter Walk/Run Test improved by 6.8% (0.4 seconds). investing.com
- 5PepGen ended Q3 2026 with $104.8 million in cash, cash equivalents and marketable securities. finance.yahoo.com
- 6Third‑quarter net loss was $19.4 million, or $0.28 per share. finance.yahoo.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.